Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale company and a contract research organization that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. They provide drug distribution and consulting related to medical business operations and patient services. They also distribute a line of brand name and generic pharmaceuticals, over-the-counter (OTC) health care products and home health care supplies and equipment to health care providers throughout the United States.

ASD Healthcare

World Courier

American Health Packaging

ICS - AmerisourceBergen

IntrinsiQ Specialty Solutions

Triose, Inc.

Besse Medical

AmerisourceBergen

Innomar Strategies

MWI Animal Health

ION Oncology Practice Network

US Bioservices

Cencora, a company building on the legacy of AmerisourceBergen, is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We connect manufacturers, providers, and patients to ensure that anyone can get the therapies they need, where and when they need them. We also help our partners bring their innovations to patients more efficiently to accelerate positive outcomes.
 
Becoming Cencora has allowed us to combine all the companies and services of AmerisourceBergen. Now, as a unified and internationally inclusive brand, we’re continuing to invest in and focus on our core pharmaceutical distribution business, while also growing our platform of pharma and biopharma services to support pharmaceutical innovation and access. Our 46,000+ worldwide team members are shaping the future of healthcare through the power of our purpose: We are united in our responsibility to create healthier futures.
 
AmerisourceBergen, now Cencora, is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $230 billion in annual revenue.

OneOncology

Profarma

Cencora

Home infusions have been prominent since the 1970s, but now is a critical time for health systems to have a comprehensive infusion strategy. 

Our Toni Giglio spoke with Dan Teich, vice president of Performance Based Contracting and Justin Whitsett, senior director, Infusion Portfolio Solution about why an infusion strategy can retain revenue and improve patient outcomes. Read the article: https://ow.ly/VzLC50QtHyT

Patients with life-threatening conditions need access to investigational medicines outside of clinical trials. Expanding Early Access Programs can help. 
 
Patrick Larcier, PharmD, MBA, Senior Director of Strategic Product Development Solutions at PharmaLex discusses the value of these programs in a guest piece for pharmaphorum. Learn about the impacts of the real-word data they give us here: https://ow.ly/si4550QtHre 

In the face of pharmacist burnout and labor shortages, partnerships with distributors are fundamental to pharmacies. Our experts guide pharmacies facing new challenges amid the shifting healthcare landscape and help them create a more significant impact in the communities they serve.

Claire Biermaas, President of Corporate Partnerships, shares how we serve as allies to pharmacies in a recent Pharmacy Times interview. https://ow.ly/XBEM50QtHoE

The cell and gene therapy (CGT) sector is entering a new era.  
 
The path to commercialization of CGT products is complex and lined with challenges that can delay market entry and impact product success. Read our experts’ step-by-step guide to CGT commercialization: https://ow.ly/4lGR50QsKcF

Cencora, formerly AmerisourceBergen, is making a positive impact in healthcare with our diverse global network of 46,000+ team members. We earned a top score of 100 on the Human Rights Campaign Foundation’s 2023-2024 Corporate Equality Index, as well as a top score of 100 on the Disability Equality Index. 

We all feel a true sense of belonging and connection to our purpose, and we’re encouraged to be our authentic selves at work. Having diverse perspectives, backgrounds, and experiences at every level of our company is what makes us stronger and more dynamic. It empowers our empathy and fuels our innovation. https://https://lnkd.in/g79XSJ7g

Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

COM:CENCORA

Cencora, Inc.

Last Close

245.69

22/11 21:00

Market Cap

44.36B

Beta: -

Volume Today

948.95K

Avg: -

Analysis Not Available